Abstract
Efficacy and safety of briakinumab in moderate to severe psoriasis patients with prior failure to TNF antagonist: Subanalysis of a 52-week phase III trial and open-label extension
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have